Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 28 contracts
Samples: Securities Purchase Agreement (Bio-Path Holdings Inc), Securities Purchase Agreement (Tenax Therapeutics, Inc.), Securities Purchase Agreement (Tenax Therapeutics, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 24 contracts
Samples: Securities Purchase Agreement (Theriva Biologics, Inc.), Securities Purchase Agreement (Beyond Air, Inc.), Securities Purchase Agreement (Myomo, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 21 contracts
Samples: Securities Purchase Agreement (Airship AI Holdings, Inc.), Securities Purchase Agreement (BioCardia, Inc.), Securities Purchase Agreement (BioCardia, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 15 contracts
Samples: Securities Purchase Agreement (Theriva Biologics, Inc.), Securities Purchase Agreement (Momentus Inc.), Securities Purchase Agreement (Ekso Bionics Holdings, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 13 contracts
Samples: Securities Purchase Agreement (Moleculin Biotech, Inc.), Securities Purchase Agreement (Revelation Biosciences, Inc.), Securities Purchase Agreement (Revelation Biosciences, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 10 contracts
Samples: Securities Purchase Agreement (Volitionrx LTD), Securities Purchase Agreement (Kaival Brands Innovations Group, Inc.), Securities Purchase Agreement (Kaival Brands Innovations Group, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock ADSs, Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement statement, or amendment or supplement thereto, with the Commission, other than a prospectus filed with the Prospectus or filing a registration statement on Form S-8 Commission pursuant to Rule 424(b) in connection with any employee benefit planthis offering.
Appears in 7 contracts
Samples: Securities Purchase Agreement (SOS LTD), Securities Purchase Agreement (SOS LTD), Securities Purchase Agreement (SOS LTD)
Subsequent Equity Sales. (a) From the date hereof until ninety thirty (9030) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 6 contracts
Samples: Securities Purchase Agreement (Aridis Pharmaceuticals, Inc.), Securities Purchase Agreement (Siyata Mobile Inc.), Securities Purchase Agreement (First Wave BioPharma, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 6 contracts
Samples: Securities Purchase Agreement (Esperion Therapeutics, Inc.), Securities Purchase Agreement (Boxlight Corp), Securities Purchase Agreement (Toughbuilt Industries, Inc)
Subsequent Equity Sales. (a) From the date hereof until ninety forty-five (9045) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 6 contracts
Samples: Securities Purchase Agreement (Momentus Inc.), Securities Purchase Agreement (Momentus Inc.), Securities Purchase Agreement (AMERICAN BATTERY TECHNOLOGY Co)
Subsequent Equity Sales. (a) From the date hereof until ninety thirty (9030) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 5 contracts
Samples: Securities Purchase Agreement (Atara Biotherapeutics, Inc.), Securities Purchase Agreement (Atara Biotherapeutics, Inc.), Securities Purchase Agreement (Checkpoint Therapeutics, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, thereto other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 5 contracts
Samples: Securities Purchase Agreement (Aptevo Therapeutics Inc.), Securities Purchase Agreement (Aptevo Therapeutics Inc.), Securities Purchase Agreement (Aptevo Therapeutics Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or Supplement, filing a registration statement on Form S-8 in connection with any employee benefit planplan or as required by any existing registration rights agreement to which the Company is a party as of the date of this Agreement.
Appears in 5 contracts
Samples: Securities Purchase Agreement (ZyVersa Therapeutics, Inc.), Securities Purchase Agreement (ZyVersa Therapeutics, Inc.), Securities Purchase Agreement (ZyVersa Therapeutics, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 5 contracts
Samples: Securities Purchase Agreement (Holdco Nuvo Group D.G Ltd.), Securities Purchase Agreement (Notable Labs, Ltd.), Securities Purchase Agreement (Galmed Pharmaceuticals Ltd.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the 90th day following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than as contemplated pursuant to the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planRegistration Rights Agreement.
Appears in 5 contracts
Samples: Securities Purchase Agreement (Progressive Care Inc.), Securities Purchase Agreement (NextPlat Corp), Securities Purchase Agreement (NextPlat Corp)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 30 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 5 contracts
Samples: Securities Purchase Agreement (BioCardia, Inc.), Securities Purchase Agreement (Staffing 360 Solutions, Inc.), Securities Purchase Agreement (Anavex Life Sciences Corp.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.17 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 4 contracts
Samples: Securities Purchase Agreement (iPower Inc.), Securities Purchase Agreement (Loop Media, Inc.), Securities Purchase Agreement (Beachbody Company, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 4 contracts
Samples: Securities Purchase Agreement (Transcode Therapeutics, Inc.), Securities Purchase Agreement (Transcode Therapeutics, Inc.), Securities Purchase Agreement (Transcode Therapeutics, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares Ordinary Shares, Ordinary Share Equivalents and/or ADSs, including the filing of Common Stock or Common Stock Equivalents any (i) registration statement, (ii) amendment to any existing registration statement or (ii) file any registration statement a prospectus or amendment or supplement theretoprospectus supplement, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planProspectus.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Therapix Biosciences Ltd.), Securities Purchase Agreement (Therapix Biosciences Ltd.), Securities Purchase Agreement (Therapix Biosciences Ltd.)
Subsequent Equity Sales. (a) From the date hereof until ninety five (905) days Trading Days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than the Prospectus or Supplement and filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Microbot Medical Inc.), Securities Purchase Agreement (Microbot Medical Inc.), Securities Purchase Agreement (Microbot Medical Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Brenmiller Energy Ltd.), Securities Purchase Agreement (Brenmiller Energy Ltd.), Securities Purchase Agreement (Check-Cap LTD)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than (a) the Prospectus or (b) filing of a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Agile Therapeutics Inc), Securities Purchase Agreement (Agile Therapeutics Inc), Securities Purchase Agreement (Agile Therapeutics Inc)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit or equity incentive plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (SpringBig Holdings, Inc.), Securities Purchase Agreement (SpringBig Holdings, Inc.), Securities Purchase Agreement (SpringBig Holdings, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Equivalents Ordinary Share Equivalents, or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Fenbo Holdings LTD), Securities Purchase Agreement (Fenbo Holdings LTD), Form of Securities Purchase Agreement (Fenbo Holdings LTD)
Subsequent Equity Sales. (a) From the date hereof until ninety fifteen (9015) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Aditxt, Inc.), Securities Purchase Agreement (JanOne Inc.), Securities Purchase Agreement (JanOne Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Effective Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Shares or Common Stock Shares Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than as contemplated pursuant to the Prospectus Registration Rights Agreement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (InMed Pharmaceuticals Inc.), Securities Purchase Agreement (InMed Pharmaceuticals Inc.), Securities Purchase Agreement (InMed Pharmaceuticals Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety seventy-five (9075) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Shares or Common Stock Equivalents Share Equivalents, or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Altamira Therapeutics Ltd.), Securities Purchase Agreement (Altamira Therapeutics Ltd.), Securities Purchase Agreement (Altamira Therapeutics Ltd.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 75 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.18 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Lexaria Bioscience Corp.), Securities Purchase Agreement (T Stamp Inc), Securities Purchase Agreement (T Stamp Inc)
Subsequent Equity Sales. (ai) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Final Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Placement Agency Agreement (Galmed Pharmaceuticals Ltd.), Placement Agency Agreement (Galmed Pharmaceuticals Ltd.), Placement Agency Agreement (Galmed Pharmaceuticals Ltd.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 15 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Transcode Therapeutics, Inc.), Securities Purchase Agreement (Transcode Therapeutics, Inc.), Securities Purchase Agreement (Staffing 360 Solutions, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or Prospectus, filing a registration statement on Form S-8 in connection with any employee benefit planplan or the filing of a registration statement or post-effective registration statement registering the Securities issued pursuant to this Agreement.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Imunon, Inc.), Securities Purchase Agreement (Imunon, Inc.), Securities Purchase Agreement (iBio, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.18 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Lexaria Bioscience Corp.), Securities Purchase Agreement (Applied Dna Sciences Inc), Securities Purchase Agreement (Moleculin Biotech, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock ADSs and/or Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planProspectus.
Appears in 3 contracts
Samples: Underwriting Agreement (Biodexa Pharmaceuticals PLC), Underwriting Agreement (Biodexa Pharmaceuticals PLC), Underwriting Agreement (Biodexa Pharmaceuticals PLC)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement contemplated herein or filing a registration statement on Form S-8 or amendment relating to the Securities contemplated in connection with any employee benefit planthis Agreement.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Future FinTech Group Inc.), Securities Purchase Agreement (Future FinTech Group Inc.), Securities Purchase Agreement (Future FinTech Group Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Amyris, Inc.), Form of Securities Purchase Agreement (Aravive, Inc.), Form of Securities Purchase Agreement (Aravive, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Notable Labs, Ltd.), Securities Purchase Agreement (Notable Labs, Ltd.), Securities Purchase Agreement (Painreform Ltd.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Shares or Common Stock Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Vision Marine Technologies Inc.), Securities Purchase Agreement (Vision Marine Technologies Inc.), Securities Purchase Agreement (Vision Marine Technologies Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any new agreement to issue or announce the any new issuance or proposed new issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Aclarion, Inc.), Securities Purchase Agreement (Aclarion, Inc.), Securities Purchase Agreement (Aclarion, Inc.)
Subsequent Equity Sales. (ai) From the date hereof until ninety ten (9010) days after the Closing Dateclosing of the Offering, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan, in each case without prior written consent of the Placement Agent.
Appears in 2 contracts
Samples: Placement Agency Agreement (Sintx Technologies, Inc.), Placement Agency Agreement (Sintx Technologies, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety ten (9010) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement, the filing of a registration statement or any amendment thereto with respect to the Common Warrant Shares or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Bone Biologics Corp), Securities Purchase Agreement (Bone Biologics Corp)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock ADSs, Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Evaxion Biotech a/S), Securities Purchase Agreement (Evaxion Biotech a/S)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit compensation plan.
Appears in 2 contracts
Samples: Form of Securities Purchase Agreement (Bone Biologics Corp), Securities Purchase Agreement (Bone Biologics Corp)
Subsequent Equity Sales. (a) From the date hereof until ninety one hundred and eighty (90180) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Underwriting Agreement (RenovoRx, Inc.), Underwriting Agreement (RenovoRx, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or Prospectus, filing a registration statement on Form S-8 in connection with any employee benefit planplan or the filing of a registration statement or post-effective registration statement registering the Securities issued pursuant to this Agreement.
Appears in 2 contracts
Samples: Securities Purchase Agreement (iBio, Inc.), Securities Purchase Agreement (iBio, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety thirty (9030) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than filing the final Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planplan or supplements or amendments to registration statements or supplements previously filed.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Virpax Pharmaceuticals, Inc.), Securities Purchase Agreement (Virpax Pharmaceuticals, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Arqit Quantum Inc.), Securities Purchase Agreement (Arqit Quantum Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety forty-five (9045) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents Equivalents, or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Nuwellis, Inc.), Securities Purchase Agreement (Nuwellis, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planSupplement.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Focus Universal Inc.), Securities Purchase Agreement (Hepion Pharmaceuticals, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing Supplement and a registration statement on Form S-8 in connection with any employee benefit equity incentive plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (180 Life Sciences Corp.), Securities Purchase Agreement (180 Life Sciences Corp.)
Subsequent Equity Sales. (a) From the date hereof until ninety [sixty (90) 60)] days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (ONCOSEC MEDICAL Inc), Securities Purchase Agreement (ONCOSEC MEDICAL Inc)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Shares or Common Stock Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than without the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planprior written consent of the Representative.
Appears in 2 contracts
Samples: Underwriting Agreement (OceanPal Inc.), Underwriting Agreement (OceanPal Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than filing the final Prospectus or filing and a registration statement on Form S-8 in connection with any employee benefit planplan and the registration statement and amendments thereto required to be filed under the transaction with Peak One Investments LP.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Safe & Green Holdings Corp.), Securities Purchase Agreement (Safe & Green Holdings Corp.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing of a registration statement on Form S-8 in connection with any employee benefit planplan or inducement grants.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Baudax Bio, Inc.), Securities Purchase Agreement (Baudax Bio, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing DateDate (the “Market Standstill”), neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Golden Minerals Co), Securities Purchase Agreement (Golden Minerals Co)
Subsequent Equity Sales. (a) From the date hereof until ninety three (903) days months after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Azitra, Inc.), Securities Purchase Agreement (Azitra, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Prospectus, or filing a registration statement on Form S-8 in connection with any employee benefit plan, or filing required to maintain the effectiveness of an effective registration statement.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Volato Group, Inc.), Securities Purchase Agreement (Volato Group, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety the one hundred eighty (90180) days after day anniversary of the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Underwriting Agreement (Scripps Safe, Inc.), Underwriting Agreement (Scripps Safe, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Equivalents Ordinary Share Equivalents, or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 F-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (VCI Global LTD), Securities Purchase Agreement (VCI Global LTD)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement, the filing of a registration statement or any amendment thereto with respect to the Common Warrant Shares or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Checkpoint Therapeutics, Inc.), Securities Purchase Agreement (Checkpoint Therapeutics, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents Equivalents, or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (SenesTech, Inc.), Securities Purchase Agreement (SenesTech, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents Equivalents, or (ii) or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planSupplement.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Digital Ally Inc), Securities Purchase Agreement (Digital Ally Inc)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (IceCure Medical Ltd.), Securities Purchase Agreement (IceCure Medical Ltd.)
Subsequent Equity Sales. (a) From the date hereof until ninety five (905) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit planplan or the filing of a registration statement or any amendment thereto with respect to the Common Warrant Shares.
Appears in 2 contracts
Samples: Securities Purchase Agreement (ONCOSEC MEDICAL Inc), Securities Purchase Agreement (ONCOSEC MEDICAL Inc)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Initial Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Invicta Media Investments, LLC), Securities Purchase Agreement (iMedia Brands, Inc.)
Subsequent Equity Sales. (ai) From the date hereof until ninety three (903) days months after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan, in each case without prior written consent of the Placement Agent.
Appears in 2 contracts
Samples: Placement Agency Agreement (Azitra, Inc.), Placement Agency Agreement (Azitra, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 30 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the a Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Netcapital Inc.), Securities Purchase Agreement (SeqLL, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) forty five 45 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Nexalin Technology, Inc.), Securities Purchase Agreement (Nexalin Technology, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit planplan or the filing of a registration statement or any amendment thereto with respect to the Warrant Shares.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Eos Energy Enterprises, Inc.), Securities Purchase Agreement (Eos Energy Enterprises, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.17 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Painreform Ltd.), Securities Purchase Agreement (Painreform Ltd.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing DateJuly 13, 2023, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit planplan or the filing of a registration statement or any amendment thereto with respect to the Warrant Shares.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Eos Energy Enterprises, Inc.), Securities Purchase Agreement (Eos Energy Enterprises, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.17 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Worksport LTD), Securities Purchase Agreement (bioAffinity Technologies, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement, the filing of a registration statement or any amendment thereto with respect to the Common Warrant Shares or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (MAIA Biotechnology, Inc.), Securities Purchase Agreement (Longeveron Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, thereto relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company (other than the Prospectus or filing a registration statement on Form S-8 S-8), in connection with any employee benefit planeach case other than as contemplated by this Agreement.
Appears in 2 contracts
Samples: Securities Purchase Agreement (U.S. Gold Corp.), Securities Purchase Agreement (U.S. Gold Corp.)
Subsequent Equity Sales. (a) From the date hereof until ninety thirty (9030) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement, the filing of a registration statement or any amendment thereto with respect to the Common Warrant Shares or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (SeaStar Medical Holding Corp), Securities Purchase Agreement (Longeveron Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety forty-five (9045) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock ADSs, Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (TC BioPharm (Holdings) PLC), Securities Purchase Agreement (TC BioPharm (Holdings) PLC)
Subsequent Equity Sales. (ai) From the date hereof until ninety _____ (90__) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than the Prospectus or the filing a registration statement on Form S-8 in connection with any employee benefit compensation plan.
Appears in 2 contracts
Samples: Placement Agency Agreement (Calidi Biotherapeutics, Inc.), Form of Placement Agency Agreement (Calidi Biotherapeutics, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety the one hundred eighty (90180) days after day anniversary of the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planProspectus.
Appears in 2 contracts
Samples: Underwriting Agreement (Safe Pro Group Inc.), Underwriting Agreement (Safe Pro Group Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents common share equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (ShiftPixy, Inc.), Securities Purchase Agreement (ShiftPixy, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.17 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (BullFrog AI Holdings, Inc.), Securities Purchase Agreement (Worksport LTD)
Subsequent Equity Sales. (a) From the date hereof until ninety forty-five (9045) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (BioSig Technologies, Inc.), Securities Purchase Agreement (Allena Pharmaceuticals, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Bluejay Diagnostics, Inc.), Securities Purchase Agreement (Bluejay Diagnostics, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety thirty (9030) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents common share equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (ShiftPixy, Inc.), Securities Purchase Agreement (ShiftPixy, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 60 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than filing the final Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Virpax Pharmaceuticals, Inc.), Securities Purchase Agreement (Virpax Pharmaceuticals, Inc.)
Subsequent Equity Sales. (a) From For the date hereof until period that is ninety (90) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Shares or Common Stock Share Equivalents or nor (ii) file any a shelf registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planprospectus.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Vicinity Motor Corp), Securities Purchase Agreement (Very Good Food Co Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety sixty (9060) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than filing the final Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (ShiftPixy, Inc.), Securities Purchase Agreement (Virpax Pharmaceuticals, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 45 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Energous Corp), Securities Purchase Agreement (Olb Group, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 30 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 S- 8 in connection with any employee benefit plan...
Appears in 1 contract
Samples: Securities Purchase Agreement (Lixte Biotechnology Holdings, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety forty-five (9045) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the 90 Trading Day anniversary of the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file Equivalents, which shall include the filing of any new registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement statement, or amendment to a registration statement, on Form S-8 in connection with any employee benefit planS-4 or Form S-8.
Appears in 1 contract
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock ADSs, Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Effective Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than (A) as contemplated pursuant to the Prospectus Registration Rights Agreement or (B) filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Samples: Securities Purchase Agreement (Digital Brands Group, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 45 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.18 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Subsequent Equity Sales. (a) From the date hereof until ninety one hundred and fifty (90150) days after the Closing Datedate hereof, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Subsequent Equity Sales. (a) From the date hereof until ninety five (905) days after Business Days following the Closing Effective Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, thereto other than the Prospectus Registration Statement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Samples: Securities Purchase Agreement (First Wave BioPharma, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 75 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Samples: Securities Purchase Agreement (9 Meters Biopharma, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after following the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit planSupplement.
Appears in 1 contract
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 120 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.. 28
Appears in 1 contract
Samples: Securities Purchase Agreement (Guardion Health Sciences, Inc.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the Prospectus Supplement or as contemplated pursuant to Section 4.18 herein or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Samples: Securities Purchase Agreement (Lexaria Bioscience Corp.)
Subsequent Equity Sales. (a) From the date hereof until ninety (90) 90 days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock Ordinary Shares or Common Stock Ordinary Share Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement on Form S-8 in connection with any employee benefit plan.
Appears in 1 contract
Subsequent Equity Sales. (a) From the date hereof until ninety (90) days after the 60 day anniversary of the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file Equivalents, which shall include the filing of any new registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement statement, or amendment to a registration statement, on Form S-8 in connection with any employee benefit planS-4 or Form S-8.
Appears in 1 contract
